$2.29
33.87% yesterday
Nasdaq, Feb 28, 05:18 pm CET
ISIN
US4277461020
Symbol
HRTX
Sector
Industry

Heron Therapeutics Inc Stock price

$1.71
-0.10 5.52% 1M
-0.27 13.64% 6M
+0.18 11.76% YTD
-0.89 34.23% 1Y
-5.39 75.92% 3Y
-16.76 90.74% 5Y
-10.87 86.41% 10Y
Nasdaq, Closing price Wed, Feb 26 2025
+0.03 1.79%
ISIN
US4277461020
Symbol
HRTX
Sector
Industry

Key metrics

Market capitalization $311.79m
Enterprise Value $419.15m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.04
P/S ratio (TTM) P/S ratio 2.26
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 12.13%
Revenue (TTM) Revenue $137.74m
EBIT (operating result TTM) EBIT $-25.92m
Free Cash Flow (TTM) Free Cash Flow $-9.61m
Cash position $70.89m
EPS (TTM) EPS $-0.18
P/E forward negative
P/S forward 1.85
EV/Sales forward 2.61
Short interest 26.19%
Show more

Is Heron Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Heron Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Heron Therapeutics Inc forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Heron Therapeutics Inc forecast:

Buy
100%

Financial data from Heron Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
138 138
12% 12%
100%
- Direct Costs 38 38
44% 44%
28%
99 99
81% 81%
72%
- Selling and Administrative Expenses 98 98
16% 16%
71%
- Research and Development Expense 24 24
56% 56%
18%
-23 -23
80% 80%
-17%
- Depreciation and Amortization 2.63 2.63
12% 12%
2%
EBIT (Operating Income) EBIT -26 -26
79% 79%
-19%
Net Profit -28 -28
77% 77%
-20%

In millions USD.

Don't miss a Thing! We will send you all news about Heron Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Heron Therapeutics Inc Stock News

Neutral
Seeking Alpha
about 24 hours ago
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Melissa Jarel - Executive Director, Legal Craig Collard - Chief Executive Officer Ira Duarte - Executive Vice President, Chief Financial Officer Bill Forbes - Executive Vice President, Chief Development Officer Kevin Warner - Senior Vice President, Medical Affairs, Strategy...
Neutral
PRNewsWire
one day ago
Achieved Q4 2024 GAAP Net Income of $3.6 million Generated full-year 2024 Net Revenue of $144.2 million, up 14% year-over-year Delivered full-year 2024 adjusted EBITDA of $8.6 million Generated ZYNRELEF® Q4 2024 Net Revenue of $8.5 million and launched the ZYNRELEF Vial Access Needle ("VAN") in December 2024 U.S. District Court ruled in favor of Heron in patent lawsuit against Fresenius Kabi US...
Neutral
PRNewsWire
15 days ago
CARY, N.C., Feb. 13, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Thursday, February 27, 2025, at 8:00 a.m.
More Heron Therapeutics Inc News

Company Profile

Heron Therapeutics, Inc. is a biotechnology company, which engages in the development of pharmaceutical products for patients suffering from cancer. Its products portfolio include SUSTOL, Cinvanti, HTX-011, and HTX-034. The company was founded in February 1983 and is headquartered in Redwood City, CA.

Head office United States
CEO Craig Collard
Employees 126
Founded 1983
Website www.herontx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today